ABBV Q2 2026 Earnings Call Summary

AbbVie Q2 2026 Earnings Call Summary

1. Key Financial Results and Metrics

Adjusted Earnings Per Share (EPS): $3.65, exceeding guidance by $0.06.
Total Net Revenues: Nearly $17 billion, up 10.2% year-over-year, beating expectations by $300 million.
Adjusted Gross Margin: 84.7% of sales.
Adjusted R&D Expense: 13.6% of sales.
Adjusted SG&A Expense: 21% of sales.
Adjusted Operating Margin: 48.3% of sales.
Net Interest Expense: $679 million.
Adjusted Tax Rate: 14.7%.

2. Strategic Updates and Business Highlights

Sales Growth: Strong performance from SKYRIZI, RINVOQ, and the neuroscience portfolio, each growing over 20%.
Immunology Revenue: $8.8 billion, with SKYRIZI sales at $5.5 billion (up 24%).
Acquisition of Apogee Therapeutics: Aimed at enhancing AbbVie's immunology portfolio with multiple assets in dermatology and respiratory diseases.
Regulatory Approvals: Recent approvals for Decnapaz in the U.S. and QLIPTA in Europe, among others, with significant sales potential anticipated.
Pipeline Progress: Advancements in R&D, including approvals for RINVOQ in vitiligo and alopecia areata, and strong data supporting upcoming launches.

3. Forward Guidance and Outlook

Revenue Guidance: Increased by $300 million to approximately $67.6 billion for the year.
Adjusted EPS Guidance: Updated to a range of $13.87 to $14.07, reflecting strong performance and anticipated dilution from the Apogee acquisition.
Third Quarter Expectations: Projected net revenues of approximately $17.2 billion and adjusted EPS between $3.84 and $3.88.

4. Bad News, Challenges, or Points of Concern

Decline in HUMIRA Sales: Down 36.1% to $706 million due to biosimilar competition.
Oncology Performance: Total oncology revenues declined 2.4%, with IMBRUVICA sales down 29.4% due to pricing pressures.
Market Competition: Concerns regarding the crowded landscape for new treatments in immunology and oncology, particularly with emerging therapies for conditions like vitiligo and alopecia areata.
Regulatory Risks: Potential delays or challenges in securing approvals for new therapies and maintaining patent protections.

5. Notable Q&A Insights

SKYRIZI Subcutaneous Approval: Confidence expressed in upcoming FDA approval for subcutaneous formulation, expected to drive sales acceleration.
Competitive Landscape in Immunology: SKYRIZI's strong positioning despite new entrants, with no significant impact observed from competitor launches.
Tevapadon Launch in Parkinson's Disease: Anticipated modest initial ramp-up in sales due to Medicare formulary timing, but long-term potential remains strong.
Bretasilocin Differentiation: Emphasis on the unique safety profile and dosing convenience compared to other psychedelic treatments, with ongoing studies to assess efficacy at higher doses.
Pipeline Management Post-Apogee Acquisition: No deprioritization of existing assets in atopic dermatitis; all pipeline assets are being advanced concurrently.

Overall, AbbVie reported strong financial results and strategic advancements, with a positive outlook for the remainder of 2026, despite facing competitive pressures and challenges in specific therapeutic areas.

ABBV — AbbVie Inc.